The Crohn's & Colitis Foundation of America Company Profile

09:01 EDT 20th June 2018 | BioPortfolio

News Articles [840 Associated News Articles listed on BioPortfolio]

Late-Onset Crohn's Disease Resembles Ulcerative Colitis

Crohn's disease (CD) diagnosed at age 55 years or later resembles ulcerative colitis (UC) and should be considered a distinct subgroup of inflammatory bowel disease (IBD), researchers report. Reuter...

Obesity increases risk for surgery in patients with ulcerative colitis

Amanda M. LynnPatients with ulcerative colitis who have a higher BMI are at increased risk for bowel resection, according to research presented at the Crohn’s & Colitis Congress.Amanda M. Lynn, MD, ...

Sandoz Receives EC Approval For Zessly As Remicade Biosimilar

NewsZessly is approved for use in all indications of the reference medicine, including rheumatoid arthritis, adult Crohn's disease, pediatric Crohn's disease, adult ulcerative colitis, pediatric ulcer...

Genetic Mutation Linked to Crohn's and Parkinson's Diseases

The inflammatory bowel diseases (IBD) are composed of two major subtypes, Crohn’s disease (CD) and ulcerative colitis (UC), which are...

uBiome Sponsors Annual Fundraising Walk, SF Take Steps, to Support the Crohn’s and Colitis Foundation

On May 5th, uBiome, the leader in microbial genomics, will be sponsoring SF Take Steps, hosted by the Northern California Chapter of the Crohn’s and Colitis Foundation, for the second consecutive ye...

Janssen to Codevelop Theravance's TD-1473 in $1B+ Collaboration

Johnson & Johnson’s Janssen Biotech will codevelop Theravance’s TD-1473 and related backup compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease,...

Novartis' Sandoz scores EU approval for Remicade biosimilar

The European Commission has given its approval to Sandoz, Novartis’ generics and biosimilars unit, for its biosimilar version of Janssen’s Remicade (infliximab) and other products, known as Zessly...

Frank Russomano Elected to National Board of Trustees of Crohn’s & Colitis Foundation

President and CEO of US HealthConnect Inc. leverages 25 years of experience in healthcare education and personal family experience with Crohn’s Disease to help the Foundation meet its mission FORT W...

Drugs and Medications [765 Associated Drugs and Medications listed on BioPortfolio]

Shiseido perfect refining foundation [SHISEIDO AMERICA INC.]

SHISEIDO Perfect Refining Foundation

Shiseido white lucent brightening spot-control foundation (refill) [SHISEIDO AMERICA INC.]

SHISEIDO WHITE LUCENT Brightening Spot-Control Foundation (Refill)

Esika [Ventura Corporation (San Juan, P.R)]

ēsika 3-in-1 Pro Make Up Foundation SPF 20

Sheer cover mineral foundation [Guthy-Renker LLC]

Sheer Cover Mineral Foundation SPF-15

Cle de peau beaute silky foundation i [SHISEIDO CO., LTD.]

CPB Silky Cream Foundation I

PubMed Articles [1388 Associated PubMed Articles listed on BioPortfolio]

Plasma microRNA Profile Differentiates Crohn's Colitis From Ulcerative Colitis.

Inflammatory bowel disease (IBD) is commonly divided into 2 entities: Crohn's disease (CD) and ulcerative colitis (UC). Differentiating between these entities when dealing with IBD confined to the col...

2nd N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn's Disease or Ulcerative Colitis.

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.

The unfinished symphony: golimumab therapy for anti-TNF refractory Crohn's disease.

Golimumab is approved for the treatment of moderate-to-severely active ulcerative colitis. However, there have been no formal trials to date to assess its utility in Crohn's disease (CD). Our aim was ...

Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis.

Alterations in short chain fatty acid metabolism, particularly butyrate, have been reported in inflammatory bowel disease, but results have been conflicting because of small study numbers and failure ...

Clinical Trials [1406 Associated Clinical Trials listed on BioPortfolio]

Risk Factors for Microscopic Colitis

Microscopic colitis is a common cause of watery diarrhea, particularly in the elderly. Although the incidence is comparable to ulcerative colitis and Crohn's disease, the etiology is unkno...

A Phase 2, Randomized, Double-Blind, Dose-Ranging Study With Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active ulcerative colitis or Crohn...

Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease

The purpose of this study is to monitor ongoing safety in subjects with ulcerative colitis (UC) and Crohn's disease (CD) and to provide access to vedolizumab for qualifying subjects who, i...

Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease

The purpose of this study is to assess the concentration of vedolizumab in breast milk of lactating women with active ulcerative colitis (UC) or Crohn's disease (CD) who are receiving vedo...

Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis

Hypothesis:In patients with ulcerative colitis and Crohn's disease diagnosed with mild or moderate anaemia: 1. iron supplementation will increase disease activity and oxidative stress ...

Companies [2291 Associated Companies listed on BioPortfolio]

RMEI Medical Education (RMEI) and Crohn's & Colitis Foundation

The Crohn's & Colitis Foundation (the Foundation) is the largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases (IBD). The F...

The Crohn's & Colitis Foundation of America

Crohns & Colitis Foundation of America

Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract, affects approximately 500,000 Americans, including approximately 100,000 pediatric patients. The cause of Crohn's diseas...

Crohn's & Colitis Foundation of America

The Crohn's & Colitis Foundation of America is the largest non-profit, volunteer-driven organization dedicated to finding a cure for Crohn's disease and ulcerative colitis, and it ranks third among le...

Crohn'sAdvocate Program

Developed as a support and advocacy program for the half a million Americans affected by Crohn's disease, the Crohn'sAdvocate(TM) program was launched nearly a year ago by UCB. The program takes a 36...

More Information about "The Crohn's & Colitis Foundation of America" on BioPortfolio

We have published hundreds of The Crohn's & Colitis Foundation of America news stories on BioPortfolio along with dozens of The Crohn's & Colitis Foundation of America Clinical Trials and PubMed Articles about The Crohn's & Colitis Foundation of America for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Crohn's & Colitis Foundation of America Companies in our database. You can also find out about relevant The Crohn's & Colitis Foundation of America Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record